Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Bisphosphonates Reduce Bone Toughness Over Time

Will Boggs, MD  |  

Dr. Burr adds, “It has been shown that the ‘half-life’ of bisphosphonates in bone may be 10 years. This means that once treatment is stopped, bone loss will not resume right away, and in fact may require 5–10 years for significant bone loss to occur [depending on the location, hip or vertebrae].”

Reference

ADVERTISEMENT
SCROLL TO CONTINUE
  1. Burr DB. Fifty years of bisphosphonates: What are their mechanical effects on bone? Bone. 2020 Sep;138:115518. Epub 2020 Jul 3.

Related Articles

    Diagnosis, Management of Medication-Induced Osteonecrosis of the Bone

    Prior to the widespread use of bisphosphonates for the manage­ment of osteoporosis, multiple myeloma and metastatic cancer to the skeletal system, osteonecrosis of the jawbones was an infrequent condition seen after radiation for oral cancers (osteoradionecrosis) and in chronic odontogenic infections.1 Since the mid-2000s, osteonecrosis of the jawbones has been noted to occur as a…

    Osteoporosis Experts Discuss Bisphosphonate Holidays

    ACR CONVERGENCE 2020—Bisphosphonates are an important treatment for millions of older Americans with osteoporosis because the drugs inhibit osteoclastic bone resorption to reduce the risk of painful, debilitating fractures.1 More than 20 years ago, data emerged that bisphosphonates have a long terminal half-life.2 So after years of therapy, could some patients take a drug holiday?…